Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Luisa-Sophie Schneider has a total of 215 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dysfunction of the episodic memory network in the Alzheimer’s disease cascade

    by René Lattmann, Niklas Vockert, Jose Bernal, Judith Wesenberg, Yanin Suksangkharn, Renat Yakupov, Hartmut Schütze, Wenzel Glanz, Enise Incesoy, Michaela Butryn, et al.

    Alzheimer’s disease (AD) is a major cause of dementia and cognitive decline. Here, we assessed how episodic memory (EM) network dysfunction, a hallmark of AD, is related to the longitudinal progression of AD biomarkers, neurodegeneration and cognition using data from the DZNE DELCODE study. This data set includes over 1000 longitudinal functional magnetic resonance imaging measurements of EM network function. We related activation and deactivation of EM to individual disease progression scores from a disease progression model. Voxel-wise analyses revealed widespread loss of deactivation and activation with disease progression. Trajectories for the loss of deactivation were nonlinear, associated with amyloid- and tau-positivity and visually preceded trajectories of cognitive decline. The relationship between deactivation and cognitive decline was partly independent of neurodegeneration. Our results provide evidence that synaptic dysfunction and neurodegeneration are independent drivers of cognitive decline, providing a rationale for targeting synaptic dysfunction along the AD cascade.


  • Open Access

    A computational ontology framework for the synthesis of multi-level pathology reports from brain MRI scans

    by Devesh Singh, Alice Grazia, Achim Reiz, Andreas Hermann, Slawek Altenstein, Lukas Beichert, Alexander Bernhardt, Katharina Buerger, Michaela Butryn, Peter Dechent, et al.

    Background: Convolutional neural network (CNN) based volumetry of MRI data can help differentiate Alzheimer's disease (AD) and the behavioral variant of frontotemporal dementia (bvFTD) as causes of cognitive decline and dementia. However, existing CNN-based MRI volumetry tools lack a structured hierarchical representation of brain anatomy, which would allow for aggregating regional pathological information and automated computational inference. Objective: Develop a computational ontology pipeline for quantifying hierarchical pathological abnormalities and visualize summary charts for brain atrophy findings, aiding differential diagnosis. Methods: Using FastSurfer, we segmented brain regions and measured volume and cortical thickness from MRI scans pooled across multiple cohorts (N = 3433; ADNI, AIBL, DELCODE, DESCRIBE, EDSD, and NIFD), including healthy controls, prodromal and clinical AD cases, and bvFTD cases. Employing the Web Ontology Language (OWL), we built a semantic model encoding hierarchical anatomical information. Additionally, we created summary visualizations based on sunburst plots for visual inspection of the information stored in the ontology. Results: Our computational framework dynamically estimated and aggregated regional pathological deviations across different levels of neuroanatomy abstraction. The disease similarity index derived from the volumetric and cortical thickness deviations achieved an AUC of 0.88 for separating AD and bvFTD, which was also reflected by distinct atrophy profile visualizations. Conclusions: The proposed automated pipeline facilitates visual comparison of atrophy profiles across various disease types and stages. It provides a generalizable computational framework for summarizing pathologic findings, potentially enhancing the physicians’ ability to evaluate brain pathologies robustly and interpretably.


  • Open Access

    Blood biomarkers confirm subjective cognitive decline (SCD) as a distinct molecular and clinical stage within the NIA-AA framework of Alzheimer´s disease

    by David Mengel, Ester Soter, Julia Maren Ott, Madeleine Wacker, Alejandra Leyva, Oliver Peters, Julian Hellmann-Regen, Luisa-Sophie Schneider, Xiao Wang, Josef Priller, et al.

    Subjective cognitive decline (SCD) is proposed as an indicator of transitional disease stage 2 in the Alzheimer’s disease (AD) continuum. However, molecular and particularly longitudinal fluid biomarker data for this stage are still limited. This study aimed to determine whether blood-based biomarkers in amyloid-positive individuals with SCD (A + SCD) support the notion of stage 2 as a distinct stage between stages 1 and 3 of AD and to identify those at high risk for clinical progression. In a prospective multicenter study (DELCODE) involving 457 participants across the AD continuum, we analyzed plasma phospho-tau 181 (p181) and neurofilament light chain (NfL) and assessed their association with longitudinal cognition, hippocampal atrophy, and AD clinical stage transition. The results showed that baseline plasma p181 levels were elevated and increased more rapidly in A + SCD individuals compared to amyloid-positive cognitively unimpaired (A + CU) individuals (stage 1). NfL levels rose across A + CU, A + SCD, and amyloid-positive mild cognitive impairment (A + MCI, stage 3). In A + SCD, but not in A + CU, higher p181 levels predicted cognitive decline (PACC5) and transition to MCI. In conclusion, plasma p181 provides molecular biomarker evidence supporting A + SCD as a pre-dementia AD stage (stage 2) distinct from A + CU (stage 1) and helps identify individuals at risk for cognitive decline early in the AD continuum.


  • Open Access

    Linking higher amyloid beta 1‐38 (Aβ(1‐38)) levels to reduced Alzheimer's disease progression risk

    by Luisa Sophie Schneider, Silka Dawn Freiesleben, Gerard van Breukelen, Xiao Wang, Frederic Brosseron, Michael T. Heneka, Stefan Teipel, Luca Kleineidam, Melina Stark, Nina Roy‐Kluth, et al.

    INTRODUCTION: The beneficial effects of amyloid beta 1‐38, or Aβ(1‐38), on Alzheimer's disease (AD) progression in humans in vivo remain controversial. We investigated AD patients' cerebrospinal fluid (CSF) Aβ(1‐38) and AD progression. METHODS: Cognitive function and diagnostic change were assessed annually for 3 years in 177 Aβ‐positive participants with subjective cognitive decline (SCD), mild cognitive impairment (MCI), and dementia from the German Center for Neurodegenerative Diseases (DZNE) longitudinal cognitive impairment and dementia study (DELCODE) cohort using the Mini‐Mental State Examination (MMSE), Preclinical Alzheimer's Cognitive Composite (PACC), Clinical Dementia Rating (CDR), and National Institute of Neurological and Communicative Disorders and Stroke–Alzheimer's Disease and Related Disorders Association (NINCDS‐ADRDA) criteria. Mixed linear and Cox regression analyses were conducted. CSF was collected at baseline. RESULTS: Higher Aβ(1‐38) levels were associated with slower PACC ( p  = 0.001) and slower CDR Sum of Boxes (CDR‐SB) ( p  = 0.002) but not MMSE decline. Including Aβ(1‐40) beyond Aβ(1‐38) in the model confirmed an association of Aβ(1‐38) with slower PACC decline ( p  = 0.005), but not with CDR‐SB or MMSE decline. In addition, higher Aβ(1‐38) baseline levels were associated with a reduced dementia conversion risk. DISCUSSION: Further research is needed to understand the role of Aβ(1‐38) in AD and its potential for future therapeutic strategies. Highlights: This study not only replicates but also extends the existing findings on the role of Aβ(1‐38) (amyloid beta 1‐38) in Alzheimer's disease (AD) in humans in vivo. Higher baseline Aβ(1‐38) levels were associated with a decreased risk of conversion to AD dementia in subjective cognitive decline (SCD) and mild cognitive impairment (MCI). Different linear‐mixed regression models suggest an association between higher Aβ(1‐38) baseline levels and slower Preclinical Alzheimer's Cognitive Composite (PACC) and Clinical Dementia Rating Sum of Boxes (CDR‐SB) decline. Including Aβ(1‐40) beyond Aβ(1‐38) in the model confirmed a link between Aβ(1‐38) and PACC decline, but showed no association of Aβ(1‐38) on CDR‐SB and Mini‐Mental State Examination (MMSE) decline. The impact of short Aβ isoforms in AD progression might have been under‐investigated These findings underscore the urgent need for additional research on the role of these shorter Aβ peptides in AD, as they may hold key insights for future therapeutic strategies.


  • Open Access

    Blood-based quantification of Aβ oligomers indicates impaired clearance from brain in ApoE ε4 positive subjects

    by Lara Blömeke, Fabian Rehn, Marlene Pils, Victoria Kraemer-Schulien, Anneliese Cousin, Janine Kutzsche, Tuyen Bujnicki, Silka D. Freiesleben, Luisa-Sophie Schneider, Lukas Preis, et al.

    Background: Quantification of Amyloid beta (Aβ) oligomers in plasma enables early diagnosis of Alzheimer’s Disease (AD) and improves our understanding of underlying pathologies. However, quantification necessitates an extremely sensitive and selective technology because of very low Aβ oligomer concentrations and possible interference from matrix components. Methods: In this report, we developed and validated a surface-based fluorescence distribution analysis (sFIDA) assay for quantification of Aβ oligomers in plasma. Results: The blood-based sFIDA assay delivers a sensitivity of 1.8 fM, an inter- and intra-assay variation below 20% for oligomer calibration standards and no interference with matrix components. Quantification of Aβ oligomers in 359 plasma samples from the DELCODE cohort reveals lower oligomer concentrations in subjective cognitive decline and AD patients than healthy Control participants. Conclusions: Correlation analysis between CSF and plasma oligomer concentrations indicates an impaired clearance of Aβ oligomers that is dependent on the ApoE ε4 status.


  • Open Access

    Cognitive reserve against Alzheimer’s pathology is linked to brain activity during memory formation

    by Niklas Vockert, Judith Machts, Luca Kleineidam, Aditya Nemali, Enise I. Incesoy, Jose Bernal, Hartmut Schütze, Renat Yakupov, Oliver Peters, Daria Gref, et al.

    The cognitive reserve (CR) hypothesis posits that individuals can differ in how their brain function is disrupted by pathology associated with aging and neurodegeneration. Here, we test this hypothesis in the continuum from cognitively normal to at-risk stages for Alzheimer’s Disease (AD) to AD dementia using longitudinal data from 490 participants of the DELCODE multicentric observational study. Brain function is measured using task fMRI of visual memory encoding. Using a multivariate moderation analysis, we identify a CR-related activity pattern underlying successful memory encoding that moderates the detrimental effect of AD pathological load on cognitive performance. CR is mainly represented by a more pronounced expression of the task-active network encompassing deactivation of the default mode network (DMN) and activation of inferior temporal regions including the fusiform gyrus. We devise personalized fMRI-based CR scores that moderate the impact of AD pathology on cognitive performance and are positively associated with years of education. Furthermore, higher CR scores attenuate the effect of AD pathology on cognitive decline over time. Our findings primarily provide evidence for the maintenance of core cognitive circuits including the DMN as the neural basis of CR. Individual brain activity levels of these areas during memory encoding have prognostic value for future cognitive decline.


  • Open Access

    A generalizable data-driven model of atrophy heterogeneity and progression in memory clinic settings

    by Hannah Baumeister, Jacob W Vogel, Philip S Insel, Luca Kleineidam, Steffen Wolfsgruber, Melina Stark, Helena M Gellersen, Renat Yakupov, Matthias C Schmid, Falk Lüsebrink, et al.

    Memory clinic patients are a heterogeneous population representing various aetiologies of pathological aging. It is unknown if divergent spatiotemporal progression patterns of brain atrophy, as previously described in Alzheimer’s disease (AD) patients, are prevalent and clinically meaningful in this group of older adults. To uncover distinct atrophy subtypes, we applied the Subtype and Stage Inference (SuStaIn) algorithm to baseline structural MRI data from 813 participants enrolled in the DELCODE cohort (mean ± SD age = 70.67 ± 6.07 years, 52% females). Participants were cognitively unimpaired (CU; n = 285) or fulfilled diagnostic criteria for subjective cognitive decline (SCD; n = 342), mild cognitive impairment (MCI; n = 118), or dementia of the Alzheimer’s type (n = 68). Atrophy subtypes were compared in baseline demographics, fluid AD biomarker levels, the Preclinical Alzheimer Cognitive Composite (PACC-5), as well as episodic memory and executive functioning. PACC-5 trajectories over up to 240 weeks were examined. To test if baseline atrophy subtype and stage predicted clinical trajectories before manifest cognitive impairment, we analysed PACC-5 trajectories and MCI conversion rates of CU and SCD participants. Limbic-predominant and hippocampal-sparing atrophy subtypes were identified. Limbic-predominant atrophy first affected the medial temporal lobes, followed by further temporal and, finally, the remaining cortical regions. At baseline, this subtype was related to older age, more pathological AD biomarker levels, APOE ε4 carriership, and an amnestic cognitive impairment. Hippocampal-sparing atrophy initially occurred outside the temporal lobe with the medial temporal lobe spared up to advanced atrophy stages. This atrophy pattern also affected individuals with positive AD biomarkers and was associated with more generalised cognitive impairment. Limbic-predominant atrophy, in all and in only unimpaired participants, was linked to more negative longitudinal PACC-5 slopes than observed in participants without or with hippocampal-sparing atrophy and increased the risk of MCI conversion. SuStaIn modelling was repeated in a sample from the Swedish BioFINDER-2 cohort. Highly similar atrophy progression patterns and associated cognitive profiles were identified. Cross-cohort model generalizability, both on the subject and group level, were excellent, indicating reliable performance in previously unseen data. The proposed model is a promising tool for capturing heterogeneity among older adults at early at-risk states for AD in applied settings. The implementation of atrophy subtype- and stage-specific end-points may increase the statistical power of pharmacological trials targeting early AD.


  • Open Access

    The Cerebrospinal Fluid Free-Glycans Hex1 and HexNAc1Hex1Neu5Ac1 as Potential Biomarkers of Alzheimer’s Disease

    by Lynn Krüger, Karina Biskup, Carola G. Schipke, Bianca Kochnowsky, Luisa-Sophie Schneider, Oliver Peters, Véronique Blanchard

    Alzheimer’s disease (AD) is the most common neurodegenerative disorder, affecting a growing number of elderly people. In order to improve the early and differential diagnosis of AD, better biomarkers are needed. Glycosylation is a protein post-translational modification that is modulated in the course of many diseases, including neurodegeneration. Aiming to improve AD diagnosis and differential diagnosis through glycan analytics methods, we report the glycoprotein glycome of cerebrospinal fluid (CSF) isolated from a total study cohort of 262 subjects. The study cohort consisted of patients with AD, healthy controls and patients suffering from other types of dementia. CSF free-glycans were also isolated and analyzed in this study, and the results reported for the first time the presence of 19 free glycans in this body fluid. The free-glycans consisted of complete or truncated N-/O-glycans as well as free monosaccharides. The free-glycans Hex1 and HexNAc1Hex1Neu5Ac1 were able to discriminate AD from controls and from patients suffering from other types of dementia. Regarding CSF N-glycosylation, high proportions of high-mannose, biantennary bisecting core-fucosylated N-glycans were found, whereby only about 20% of the N-glycans were sialylated. O-Glycans and free-glycan fragments were less sialylated in AD patients than in controls. To conclude, this comprehensive study revealed for the first time the biomarker potential of free glycans for the differential diagnosis of AD.


  • Open Access

    Different inflammatory signatures based on CSF biomarkers relate to preserved or diminished brain structure and cognition

    by Dayana Hayek, Gabriel Ziegler, Luca Kleineidam, Frederic Brosseron, Aditya Nemali, Niklas Vockert, Kishore A. Ravichandran, Matthew J. Betts, Oliver Peters, Luisa-Sophie Schneider, et al.

    Neuroinflammation is a hallmark of Alzheimer’s disease (AD) and both positive and negative associations of individual inflammation-related markers with brain structure and cognitive function have been described. We aimed to identify inflammatory signatures of CSF immune-related markers that relate to changes of brain structure and cognition across the clinical spectrum ranging from normal aging to AD. A panel of 16 inflammatory markers, Aβ42/40 and p-tau181 were measured in CSF at baseline in the DZNE DELCODE cohort (n = 295); a longitudinal observational study focusing on at-risk stages of AD. Volumetric maps of gray and white matter (GM/WM; n = 261) and white matter hyperintensities (WMHs, n = 249) were derived from baseline MRIs. Cognitive decline (n = 204) and the rate of change in GM volume was measured in subjects with at least 3 visits (n = 175). A principal component analysis on the CSF markers revealed four inflammatory components (PCs). Of these, the first component PC1 (highly loading on sTyro3, sAXL, sTREM2, YKL-40, and C1q) was associated with older age and higher p-tau levels, but with less pathological Aβ when controlling for p-tau. PC2 (highly loading on CRP, IL-18, complement factor F/H and C4) was related to male gender, higher body mass index and greater vascular risk. PC1 levels, adjusted for AD markers, were related to higher GM and WM volumes, less WMHs, better baseline memory, and to slower atrophy rates in AD-related areas and less cognitive decline. In contrast, PC2 related to less GM and WM volumes and worse memory at baseline. Similar inflammatory signatures and associations were identified in the independent F.ACE cohort. Our data suggest that there are beneficial and detrimental signatures of inflammatory CSF biomarkers. While higher levels of TAM receptors (sTyro/sAXL) or sTREM2 might reflect a protective glia response to degeneration related to phagocytic clearance, other markers might rather reflect proinflammatory states that have detrimental impact on brain integrity.


  • Open Access

    Altered limbic functional connectivity in individuals with subjective cognitive decline: Converging and diverging findings across Chinese and German cohorts

    by Xueyan Jiang, Xiaochen Hu, Marcel Daamen, Xiaoqi Wang, Chunqiu Fan, Dix Meiberth, Annika Spottke, Sandra Roeske, Klaus Fliessbach, Eike Jakob Spruth, et al.

    INTRODUCTION: It remains unclear whether functional brain networks are consistently altered in individuals with subjective cognitive decline (SCD) of diverse ethnic and cultural backgrounds and whether the network alterations are associated with an amyloid burden.METHODS: Cross‐sectional resting‐state functional magnetic resonance imaging connectivity (FC) and amyloid‐positron emission tomography (PET) data from the Chinese Sino Longitudinal Study on Cognitive Decline and German DZNE Longitudinal Cognitive Impairment and Dementia cohorts were analyzed.RESULTS: Limbic FC, particularly hippocampal connectivity with right insula, was consistently higher in SCD than in controls, and correlated with SCD‐plus features. Smaller SCD subcohorts with PET showed inconsistent amyloid positivity rates and FC–amyloid associations across cohorts.DISCUSSION: Our results suggest an early adaptation of the limbic network in SCD, which may reflect increased awareness of cognitive decline, irrespective of amyloid pathology. Different amyloid positivity rates may indicate a heterogeneous underlying etiology in Eastern and Western SCD cohorts when applying current research criteria. Future studies should identify culture‐specific features to enrich preclinical Alzheimer's disease in non‐Western populations.Highlights: Common limbic hyperconnectivity across Chinese and German subjective cognitive decline (SCD) cohorts was observed. Limbic hyperconnectivity may reflect awareness of cognition, irrespective of amyloid load. Further cross‐cultural harmonization of SCD regarding Alzheimer's disease pathology is required.